MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved ...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance ...
It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable ...
SHREVEPORT, La. -- No one likes to get a colonoscopy, but it's an important tool in the fight against colon cancer. There is an easier way: Cologuard is a non-invasive, effective, and affordable ...
The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...
The FDA approved Exact Sciences’ Cologuard Plus multitarget stool DNA test to screen adults aged 45 years or older at average risk for colorectal cancer, according to a company press release. Compared ...
MADISON, Wis., Oct. 22, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced late-breaking data from the pivotal ...
Data demonstrate long-term impact of the Cologuard test, a powerful tool for preventing and detecting cancer The data assessed the far-reaching benefits of the first and only multi-target stool DNA ...
Positive and Negative Predictive Value of a Non-Endoscopic Molecular Barrett’s Esophagus Detection Test in Screening Eligible Adults: Results from a Large Multicenter Population Based Clinical Trial ...
Jeff Smith was dumbfounded when he received a colon cancer screening kit in the mail. The 68-year-old Minnesota man hadn't asked for the Cologuard test, and his doctor hadn't mentioned anything about ...
Cologuard Plus™ test raises the performance bar with sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity Cologuard Plus test will minimize ...
American College of Gastroenterology (ACG) gives BLUE-C study late breaker status at 2023 annual meeting with presentation of the only head-to-head study results versus FIT at ACG High specificity for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback